Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11353
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGoodwin, Mark Den
dc.contributor.authorDobson, Julie Een
dc.contributor.authorSirlin, Claude Ben
dc.contributor.authorLim, Beng Gheeen
dc.contributor.authorStella, Damien Len
dc.date.accessioned2015-05-16T00:56:36Z
dc.date.available2015-05-16T00:56:36Z
dc.date.issued2011-10-01en
dc.identifier.citationRadiographics : A Review Publication of the Radiological Society of North America, Inc; 31(6): 1547-68en
dc.identifier.govdoc21997981en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11353en
dc.description.abstractThe use of gadolinium-based hepatocyte-specific contrast agents (HSCAs) has increased markedly since their introduction, and hepatocellular phase imaging performed with an HSCA is now a key part of the standard magnetic resonance (MR) imaging work-up for focal liver lesions. An understanding of the mechanisms of action of HSCAs helps ensure their effective use. The optimal delay for hepatocellular phase image acquisition differs between the two currently available HSCAs, gadoxetic acid and gadobenate dimeglumine, and MR imaging protocols must be adjusted accordingly. In addition, familiarity with typical and atypical appearances of benign and malignant focal liver lesions at HSCA-enhanced hepatocellular phase MR imaging, along with knowledge of the processes that are most likely to produce atypical appearances, is required to achieve optimal diagnostic accuracy.en
dc.language.isoenen
dc.subject.otherContrast Media.diagnostic useen
dc.subject.otherDiagnosis, Differentialen
dc.subject.otherGadolinium DTPA.diagnostic useen
dc.subject.otherHepatocytes.metabolismen
dc.subject.otherHumansen
dc.subject.otherLiver Diseases.diagnosisen
dc.subject.otherMagnetic Resonance Imaging.methodsen
dc.subject.otherMeglumine.analogs & derivatives.diagnostic useen
dc.subject.otherOrganometallic Compounds.diagnostic useen
dc.titleDiagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents.en
dc.typeJournal Articleen
dc.identifier.journaltitleRadiographics : a review publication of the Radiological Society of North America, Incen
dc.identifier.affiliationDepartment of Radiology, Austin Health, 145 Studley Road, Heidelberg, Melbourne, VIC 3084, Australiaen
dc.identifier.doi10.1148/rg.316115528en
dc.description.pages1547-68en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/21997981en
dc.type.austinJournal Articleen
local.name.researcherDobson, Julie E
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptRadiology-
crisitem.author.deptRadiology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

50
checked on Dec 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.